NDAORALTABLET
Approved
Apr 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Mechanism of Action
Trientine, a copper chelator, eliminates absorbed copper from the body by forming a stable complex that is then eliminated through urinary excretion. Trientine also chelates copper in the intestinal tract, reducing copper absorption.
Indications (1)
Clinical Trials (3)
Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
Started May 2026
38 enrolled
Wilson's Disease
Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride
Started Jul 2025
10 enrolled
Wilson's Disease
Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease
Started Sep 2018
77 enrolled
Wilson Disease
Loss of Exclusivity
LOE Date
May 3, 2039
160 months away
Patent Expiry
May 3, 2039
Exclusivity Expiry
Apr 28, 2029